Whether AFP can be used as the only trackable indicator for evaluating the therapeutic effect of vaginal YSTs, such as β-human chorionic gonadotropin, in gestational trophoblast diseases, remains to be determined. The gene discussed is AFP; the disease is gestational trophoblastic neoplasm.